Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

29,778 signal articles · 45 in last 24h · 148,396 total before filter · latest 2h ago
45last 24h
974last 7d
109● bullish (7d)
121● bearish (7d)
212publishers
AllMacro369Earnings115M&A98Regulatory8Product11Analyst10
✕ clear all filtersticker: TEMsentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Tempus AI (TEM) Stock May Be A Bargain Despite Its 22% Slump
Simply Wall St.60d agobearish
Tempus AI (TEM) Stock May Be A Bargain Despite Its 22% Slump

Tempus AI stock has fallen 22.4% year to date, yet the valuation checks paint a mixed picture rather than a clear bargain or clear overvaluation. This puts the recent share price weakness under scrutiny. Year to date, Tempus AI is down 22.4%, a move that raises the question of whether sentiment has swung too far relative to the company’s fundamentals. On the positive side, progress in deploying its prostate cancer AI tools in real clinical settings can support expectations for future...

Imviva’s CTA313 Lupus Drug Shows Promising Remission Results
Exec Edge127d agobearish
Imviva’s CTA313 Lupus Drug Shows Promising Remission Results

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 […]